South Africa is expected to begin piloting injectable pre-exposure prophylaxis (PrEP) in 2023, health financing mechanism Unitaid tells aidsmap. The demonstration study will be the first of many hoping to answer the single biggest challenge for a rollout there and beyond: How to take a surprisingly complicated injection out of clinics and hospitals and into communities.
Adolescent girls and young women in South Africa will be the first to access injectable PrEP using the antiretroviral drug cabotegravir every other month as part of the Unitaid-supported demonstration project. The pilot will follow regulatory approval for the drug, which Unitaid expects in early 2023.
Read the full story at Aidsmap.
Source : Aidsmap
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.